What is the appropriate treatment plan for a patient with hypotension, bradycardia, and dizziness who is taking metoprolol tartrate 25 mg twice daily and flecainide 50 mg twice daily?

Immediate Medication Adjustment Required

You must immediately reduce or discontinue metoprolol tartrate, as the combination of metoprolol 25 mg BID and flecainide 50 mg BID is causing symptomatic bradycardia and hypotension that requires urgent intervention. 1

Algorithmic Approach to Management

Step 1: Immediate Actions

• Discontinue metoprolol tartrate entirely if heart rate <50 bpm or systolic BP <90 mmHg
• If heart rate 50-60 bpm and BP 90-100 mmHg systolic, reduce metoprolol to 12.5 mg BID (half tablet)
• Continue flecainide 50 mg BID unchanged, as this is a low dose and likely necessary for arrhythmia control

Rationale: The FDA labeling explicitly lists hypotension, bradycardia, and dizziness as known adverse effects of metoprolol 1. In patients with severe intolerance, the label specifically states to "discontinue metoprolol" 1. The combination of a beta-blocker with flecainide creates additive negative chronotropic and inotropic effects 2, 3.

Step 2: Monitor Response (24-48 hours)

Check for:

• Heart rate improvement to >60 bpm
• Blood pressure normalization (systolic >100 mmHg)
• Resolution of dizziness

Step 3: Long-term Management Decision Tree

If symptoms resolve after metoprolol reduction/discontinuation:

• Continue flecainide 50 mg BID alone for rhythm control 4
• Flecainide monotherapy is reasonable for SVT management in patients without structural heart disease 4
• The 2015 ACC/AHA/HRS guidelines support flecainide as Class IIa recommendation for ongoing SVT management 4

If arrhythmia control inadequate on flecainide alone:

• Consider increasing flecainide to 100 mg BID (if tolerated and no contraindications) 4
• Alternative: Switch to diltiazem or verapamil monotherapy 4
• Do NOT restart metoprolol unless absolutely necessary and only at very low doses (12.5 mg daily)

Critical Pitfalls and Caveats

Drug Interaction Concerns

The combination of metoprolol and flecainide creates synergistic bradycardia and hypotension through multiple mechanisms 3:

• Both drugs slow AV nodal conduction
• Both have negative inotropic effects
• Flecainide can unmask sinus node dysfunction 5

A 2022 case report documented severe sinus arrest requiring temporary pacing in a patient on flecainide 50 mg, emphasizing that flecainide "can unmask sinus node dysfunction in asymptomatic patients" 5. Your patient's symptoms suggest this is occurring.

When Beta-Blocker Combination IS Beneficial

Importantly, the flecainide-metoprolol combination does improve outcomes in persistent atrial fibrillation when tolerated 2. However, this benefit only applies if the patient can tolerate the combination without symptomatic bradycardia or hypotension. A 2016 study showed the combination reduced AF recurrences but required careful dose titration 2.

Metoprolol-Specific Considerations

• Metoprolol blood levels increase substantially in hepatic impairment; if present, use extremely low doses 1
• Beta-blocker withdrawal must be gradual (1-2 weeks) if discontinuing completely to avoid rebound tachycardia 1
• However, in acute symptomatic bradycardia/hypotension, immediate discontinuation takes priority

Contraindications to Current Regimen

The 2015 ACC/AHA/HRS guidelines explicitly list as precautions for beta-blockers 4:

• Hypotension (your patient has this)
• Bradycardia (your patient has this)
• SA node dysfunction (likely present given symptoms)

Your patient meets multiple contraindications for continuing current beta-blocker dosing.

Alternative if Rhythm Control Fails

If flecainide monotherapy proves inadequate:

• Diltiazem 120-360 mg daily (long-acting formulation) is reasonable 4
• Provides rate control without the profound bradycardic effects of beta-blockers
• Class IIa recommendation for focal AT management 4

Do not use verapamil if any concern for heart failure or LV dysfunction, as it causes worse hemodynamic effects than diltiazem 4.

Monitoring After Adjustment

Once metoprolol is reduced/discontinued:

• Daily heart rate and BP checks for 1 week
• Assess for arrhythmia recurrence
• If dizziness persists despite normalized vital signs, consider other causes (orthostatic hypotension, dehydration, vestibular)

The evidence strongly supports that your patient's symptoms are medication-induced and will resolve with appropriate dose reduction 1, 6, 7, 8.